Ruthenium(II)-arene complexes with naphthalimide-tagged N,O- and N,N-chelating ligands: Synthesis and biological evaluation
Authors:
- Kesete GhebreyessusKGKesete Ghebreyessus
- Ashley PeraltaAPAshley Peralta
- Meena KatdareMKMeena Katdare
- Krishnan PrabhakaranKrishnan Prabhakaran
- Shanthi ParanawithanaSPShanthi Paranawithana
- 1 August 2015
- journal article
- Published by Elsevier in Inorganica Chimica Acta
- Vol. 434, 239-251
Abstract
No abstract availableFunding Information
- National Science Foundation (HRD-1137747)
- Hampton University Faculty Research Fund
This publication has 54 references indexed in Scilit:
- Improved reaction conditions for the synthesis of new NKP-1339 derivatives and preliminary investigations on their anticancer potentialDalton Transactions, 2014
- Current applications and future potential for bioinorganic chemistry in the development of anticancer drugsDrug Discovery Today, 2009
- Bioorganometallic chemistry—from teaching paradigms to medicinal applicationsChemical Society Reviews, 2008
- KP1019, A New Redox‐Active Anticancer Agent – Preclinical Development and Results of a Clinical Phase I Study in Tumor PatientsChemistry & Biodiversity, 2008
- From bench to bedside – preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A)Journal of Inorganic Biochemistry, 2006
- Metal-based antitumour drugs in the post genomic eraDalton Transactions, 2006
- Ruthenium Antimetastatic AgentsCurrent Topics in Medicinal Chemistry, 2004
- A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer AgentClinical Cancer Research, 2004
- Ruthenium metallopharmaceuticalsCoordination Chemistry Reviews, 2003
- Medicinal Inorganic Chemistry1999